ResultsIQ

ResultsIQ › Latest results › Aarti Drugs Limited

Aarti Drugs Limited Q4 FY25 results deck summary

NSE: AARTIDRUGS · BSE: 524348

Results deck of 6 May 2025, summarised by AI from the filing.

Revenue potential ₹4,200–4,500 cr with higher margin profile in next 5-6 years post ₹600 cr capex

Key takeaways

  1. Guidance Revenue potential ₹4,200–4,500 cr with higher margin profile in next 5-6 years post ₹600 cr capex
  2. Change FY25 revenue declined 5% to ₹2,403 cr from ₹2,533 cr in FY24
  3. Driver Capex of ₹600 cr underway for brownfield expansion, backward integration and debottlenecking

Original filing on BSE

Aarti Drugs Limited Q1 FY27 results

As filed: Revenue ₹703 cr (+19% year on year), EBITDA ₹98.2 cr (+31% year on year), PAT ₹50.1 cr (−7% year on year), EBITDA margin 14.0% (+128 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹720 cr (+6% year on year), EBITDA ₹95.8 cr (+3% year on year), PAT ₹55.3 cr (−12% year on year), EBITDA margin 13.3% (−44 bps). Score 51 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin fell 44 bps year on year. Share price after the results: +1.1% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹602 cr (+8% year on year), EBITDA ₹55.0 cr (−11% year on year), PAT ₹40.6 cr (+10% year on year), EBITDA margin 9.2% (−199 bps). Score 42 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 199 bps year on year. Tax rate -40%. Revenue fell 8% from last quarter. Share price after the results: −7.6% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹653 cr (+9% year on year), EBITDA ₹84.0 cr (+24% year on year), PAT ₹45.0 cr (+29% year on year), EBITDA margin 12.9% (+149 bps). Score 75 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 149 bps year on year. Profit fell 17% from last quarter. Share price after the results: −17.2% in 28 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹591 cr (+6% year on year), EBITDA ₹75.0 cr (+15% year on year), PAT ₹54.0 cr (+64% year on year), EBITDA margin 12.7% (+98 bps). Score 74 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 98 bps year on year. Tax rate -6%. Revenue fell 13% from last quarter. Share price after the results: −7.0% in 27 days (Nifty 500: −2.6%).
  • Q4 FY25: Revenue ₹677 cr (+9% year on year), EBITDA ₹93.0 cr (+8% year on year), PAT ₹63.0 cr (+34% year on year), EBITDA margin 13.7% (−13 bps). Score 82 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin fell 13 bps year on year. Tax rate 11%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +32.4% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹557 cr (−8% year on year), EBITDA ₹62.0 cr (−13% year on year), PAT ₹37.0 cr (0% year on year), EBITDA margin 11.1% (−59 bps). Score 29 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 59 bps year on year. Revenue fell 7% from last quarter.
  • Q2 FY25: Revenue ₹598 cr (−7% year on year), EBITDA ₹68.0 cr (−11% year on year), PAT ₹35.0 cr (−13% year on year), EBITDA margin 11.4% (−47 bps). Score 23 of 100, Below trend. EBITDA margin fell 47 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Aarti Drugs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.